Thomson Reuters Corp.
Biofrontera Prepares Market Launch in Belgium for Its Non-Melanoma Skin Cancer Drug Ameluz(R)
Biofrontera AG, a biopharmaceutical company focusing on skin cancer, has completed nearly all preparations for the launch of its non-melanoma skin cancer drug Ameluz(R) in Belgium. The company anticipates first sales in the first quarter of 2015 and has secured pricing for the Belgian market. The therapy will be